주요 연구분야 및 업적 . 최종 목표

논문
[식도암]
01. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line
treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised,
placebo-controlled, phase 3 study
2021년 : Lancet 2021 Aug 28:398:759-771

02. Adjuvant Durvalumab for Esophageal Squamous Cell Carcinoma After Neoadjuvant
Chemoradiotherapy: A Placebo-Controlled, Randomised, Double-Blind, Phase II Study
2022년 : ESMO Open 2022, vol 7 (https://doi.org/10.1016)

03. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally
advanced esophageal squamous cell carcinoma
2022년 : Cancer 2022 Jun 1, 128:2148-2158

04. Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A
Single-Arm, Phase II Study
2024년 : Cancer Res Treat. 2024; 56(2):567-579

05. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or
CD8 expression in its therapeutic effect
2021년 : Cancer Immunol Immunother 2021 May; 70 (5):1203-1211

[폐암]
06. Continuation of pembrolizumab with additional chemotherapy after progression with
PD-1/PD-L1 inhibitor monotherapy in patients with advanced non-small cell lung
cancer: a randomized, placebo-controlled phase II study
2022년 : Clinical Cancer Research 2022;28 (11): 2321-2328

07. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung
cancer treated with pralsetinib: single Korean center compassionate use experience
2021년 : European Journal of Cancer 2021;159: 167-173

08. Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a
single-arm, phase II study
2023년 : ESMO Open 2023 Nov 27;8(6):102068

09. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to
Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non？Small Cell Lung Cancer
2023년 : Cancer Res Treat 2023, Apr;55(2): 479-487

10. Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated
non-small cell lung cancer
2023년 : Transl Lung Cancer Res 2023 Sep 28;12(9):1912-1922.

11. The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to
Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non？Small Cell Lung Cancer
2023년 : Cancer Res Treat 2023, Apr;55(2): 479-487

12. Role of circulating Tumor DNA profiling in patients with non-small cell lung cancer
treated with EGFR inhibitor
2022년 : Oncology 2022 April, Vol 100 (no.4)

13. Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell
lung cancer patients with acquired resistance to first-line EGFR inhibitors
2021년 : Transl lung cancer research 2021 Feb:10:878-888

[설암]
14. Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for
locally advanced hypopharynx and base of tongue cancer
2021년 : Korean J Intern medi 2021;36:S217-S224

연구 최종 목표
01. 지난 15년간 항암약물치료의 방법에서 엄청난 변화와 발전이 이루어진 것처럼 향후 15년간 이루어질 변화와 발전에 있어 보탬이 되고자 하는 바램
02. 신연구분야 ‘면역관문억제제와의 여러 병용항암요법’ 과 ‘cancer vaccine’ 에 대한 임상연구 진행